Revance Therapeutics
RVNC
$3.32
Share price
-22.61%
Change (1 day)
-90.56%
Change (1 year)
Categories
Revance Therapeutics (RVNC) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.63 B
According to Revance Therapeutics's latest financial reports the company's total liabilities are $0.63 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Revance Therapeutics - Total liabilities on balance sheet (from 2012 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.63 B | 10.67% |
| 2022-12-31 | $0.56 B | 23.04% |
| 2021-12-31 | $0.46 B | 33.75% |
| 2020-12-31 | $0.34 B | 201.34% |
| 2019-12-31 | $0.11 B | 42.21% |
| 2018-12-31 | $80.72 M | 200.61% |
| 2017-12-31 | $26.85 M | -1.59% |
| 2016-12-31 | $27.28 M | 20.91% |
| 2015-12-31 | $22.57 M | 40.19% |
| 2014-12-31 | $16.1 M | -91.07% |
| 2013-12-31 | $0.18 B | -21.71% |
| 2012-12-31 | $0.23 B | 17.78% |
| 2011-12-31 | $0.19 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $101.94 B | 16,080.42% | 🇺🇸 USA |
 Biogen BIIB | $11.35 B | 1,702.15% | 🇺🇸 USA |
 MediciNova MNOV | $3.89 M | -99.38% | 🇺🇸 USA |